was specified by the IMV edge or IMV edge + 0.5 cm medial and lateral expansion. Results: Patient characteristics and i-IMN distribution were similar at staging and recurrence. Only laterality at time of recurrence differed: left 39 nodes, right 21 nodes (P Z 0.045). Mean depth from the skin surface was 3.4 cm (range: 1.1 cm-7.3cm). Prescriptive depths of 4 cm, 5 cm, and 6 cm resulted in geographic miss of 25%, 10.7%, and 5.3% respectively. Most i-IMN were in the first to the third (94.6%) IC space. Few were in the fourth (4.5%) or fifth (0.9%) IC. All i-IMNs were ipsilateral and most (98.2%) were within 5 cm of sternal midline: 11.6% were posterior to the sternum and 88.4% were adjacent or lateral to the sternal edge. Geographic miss or excess normal tissue exposure were dependent on selection of the sternal border used for field placement. Most i-IMN (83%) were adjacent to the IMV. Nineteen (17%) were not adjacent but were within 0.5 cm (n Z 16) of the IMV edge. Only 3 (3%) were >0.5 cm beyond the IMV edge. The IMV-CTV defined by the first e third IC encompassed 78% of i-IMN. Inclusion of the fourth IC space increased coverage to 82% while a 0.5 cm margin expansion increased coverage to 93%. Margin expansion and inclusion of the fourth IC space increased coverage to 97%. Conclusion: PET-CT studies in this series of patients with breast cancer and IMN involvement suggest that older 2D treatment techniques resulted in geographic misses of tumor and exposure of normal tissue to excess radiation. Conformal 3D treatment planning by contouring the IMV from the first-third IC space as an IMN-CTV improves coverage but may exclude a substantial number of i-IMN from the CTV. Expanding the medial and lateral borders 0.5 cm beyond the IMV edge offers further improvement and encompass almost all i-IMN identified on PET-CT imaging. Inclusion of the fourth IC space offers modest improvement and should be considered only if additional heart exposure can be avoided. ; KFSYSCC, Taipei, Taiwan Purpose/Objective(s): The definition of high-risk N0 and N1 breast cancer patients, who would benefit from regional node irradiation (RNI) or post-mastectomy radiotherapy (PMRT), is still no consensus. This study aims to identify the high-risk N0 and N1 mastectomy patients by an 18-International Journal of Radiation Oncology Biology Physics S146
Purpose/Objective(s): The 21-gene recurrence score (RS) assay is prognostic for locoregional failure among women with node-negative, estrogen-receptor-positive (ER+) breast cancer treated with tamoxifen. In ER+, node-positive, postmenopausal breast cancer patients treated on the phase III trial SWOG S8814, RS was prognostic for disease-free survival in women treated with tamoxifen alone and identified those who might not benefit from cyclophosphamide, doxorubicin and fluorouracil chemotherapy (CAF) prior to tamoxifen. We examine whether RS was prognostic for locoregional recurrence (LRR) in this node-positive population. Materials/Methods: Documentation regarding locoregional recurrence (ipsilateral chest wall or regional nodal recurrence) and use of radiotherapy was extracted from the charts of 367 patients with available RS. We excluded patients treated with mastectomy and radiation (37), those treated with breast conserving surgery without documentation of radiotherapy (9) and those with unknown surgery type (5), leaving 316 for this analysis. The effect of RS on LRR was assessed using cumulative incidence with censoring at last known contact if no LRR. If distant disease occurred first, subsequent LRR may not have been recorded. Intermediate (18-30) and high RS (>31) were grouped for the purpose of modeling. Time to LRR was tested with log-rank tests and Cox regression for multivariate models. Results: Median follow up for those without LRR was 8.6 years. There were 7 LRR events among 121 patients with low RS and 27 events among 195 patients with intermediate/high RS. Estimated ten year cumulative incidence rates were 9.7% and 16.5%, respectively (log-rank P Z 0.018). Restricted to patients who had mastectomy the differences remained significant (low RS 7.8% for n Z 91 and inter/high RS 16.8% for n Z 160, P Z 0.027). There were only 6 events among patients who had breast conserving therapy so subset analysis was not possible. A multivariate model controlling for randomized treatment (chemotherapy or not), number of positive nodes (1-3 vs 4+) and surgery type still showed higher RS was prognostic for LRR (HR Z 2.35; 95% CI Z 1.02-5.43; P Z 0.045). Conclusion: Higher RS was associated with increased LRR in an ER+, node-positive population treated with CAF followed by tamoxifen or tamoxifen alone after adjustment for treatment, type of surgery and number of positive nodes. This is the first validation of an association between RS and LRR in a node-positive cohort, suggesting that RS may be useful to assess risk of LRR. Low LRR among patients with low RS, nodepositive disease treated by mastectomy supports a prospective trial to investigate omission of radiotherapy in these patients.
